症状性颅内动脉狭窄支架置入与药物治疗随机试验长期随访
该研究延长了358例症状性重度颅内动脉狭窄(70%~99%)患者的多中心随机试验随访,中位随访7.4年。结果显示支架置入联合药物治疗与单纯药物治疗在主要复合终点(30天内卒中或死亡或30天后责任血管供血区卒中)无显著差异(14.8% vs 14.3%;HR 1.02,95%CI 0.58-1.77;P=0.97)。结论认为在药物治疗基础上加用支架并未带来额外获益。
要点
- 长期随访中,支架联合药物治疗与单纯药物治疗的主要终点无显著差异(14.8% vs 14.3%;HR 1.02,95%CI 0.58-1.77;P=0.97)。
- 责任血管供血区卒中、致残性卒中或死亡、死亡等次要终点两组间均无显著差异。
- 药物治疗是症状性重度颅内动脉狭窄长期卒中预防的基石。
核心结论
- 在症状性重度颅内动脉狭窄患者中,即使延长观察时间,在药物治疗基础上加用支架也未较单纯药物治疗带来额外获益。
研究设计与样本
- 多中心、开放标签、随机试验的延长随访,共纳入358例患者(支架组176例 vs 药物治疗组182例),中国8个中心参与。
- 患者为短暂性脑缺血发作或卒中归因于重度颅内动脉狭窄(70%~99%),招募时间为2014年3月5日至2016年11月10日,随访至2024年1月22日。
主要发现
- 中位随访7.4年(四分位距6.0-8.0年)。
- 主要复合终点(30天内卒中或死亡或30天后责任血管供血区卒中)支架组14.8% vs 药物治疗组14.3%(HR 1.02,95%CI 0.58-1.77;P=0.97),无显著差异。
- 责任血管供血区卒中支架组14.8% vs 药物治疗组14.3%(HR 1.02,95%CI 0.58-1.77;P=0.97),无显著差异。
- 致残性卒中或死亡支架组16.5% vs 药物治疗组14.3%(HR 1.12,95%CI 0.66-1.91;P=0.70),无显著差异。
- 死亡支架组9.1% vs 药物治疗组7.1%(HR 1.22,95%CI 0.58-2.58;P=0.60),无显著差异。
关键数值与推荐
- 主要终点定义为30天内卒中或死亡或30天后责任血管供血区卒中的复合终点。
- 入组标准为短暂性脑缺血发作或卒中归因于重度颅内动脉狭窄(70%~99%)。
临床怎么用
- 原文结论强调药物治疗是此类患者长期卒中预防的基石。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether the long-term benefit of stroke prevention when stenting is added to medical therapy (MT) over MT alone for symptomatic severe intracranial artery stenosis offsets the perioperative risks of the stenting has not been directly evaluated in a randomized trial. We aimed to compare the long-term (>3 years) effect of stenting versus MT alone in patients with symptomatic severe intracranial artery stenosis in a randomized trial. METHODS: We extended the follow-up of 358 subjects enrolled in a multicenter, open-label, randomized trial conducted at 8 centers in China. Patients with transient ischemic attack or stroke attributed to severe intracranial stenosis (70% to 99%) were recruited between March 5, 2014, and November 10, 2016. The primary outcome was a composite of stroke or death within 30 days or stroke in the territory of the qualifying artery beyond 30 days. Other secondary outcomes included stroke in the territory of the qualifying artery, as well as disabling stroke or death after enrollment. RESULTS: A total of 358 patients (stenting 176 versus MT 182) were recruited from March 5, 2014, and followed up till January 22, 2024. The median duration of follow-up was 7.4 years (interquartile range, 6.0-8.0). The primary outcome was not significantly different (stenting 14.8% versus MT 14.3%; hazard ratio, 1.02 [95% CI, 0.58-1.77]; P=0.97). No significant difference was found between groups for the secondary outcomes: stroke in the territory of qualifying artery (14.8% versus 14.3%; hazard ratio, 1.02 [95% CI, 0.58-1.77]; P=0.97), disabling stroke or death (16.5% versus 14.3%; hazard ratio, 1.12 [95% CI, 0.66-1.91]; P=0.70), and death (9.1% versus 7.1%; hazard ratio, 1.22 [95% CI, 0.58-2.58]; P=0.60). CONCLUSIONS: This study provides compelling evidence that, even over prolonged observed periods, the addition of stenting to MT does not confer additional benefits to MT alone in patients with symptomatic severe intracranial artery stenosis. These results underscore the importance of MT as the cornerstone of long-term stroke prevention in this patient population. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01763320.
引用
- Gao P, He X, Wang H, et al. Stenting Versus Medical Therapy for Symptomatic Intracranial Artery Stenosis: Long-Term Follow-Up of a Randomized Trial. Stroke. 2025. PMID: 40099362. doi:10.1161/STROKEAHA.124.049602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。